White House issues executive order to pave way for psychedelic drug treatments
The order, which surprised some legal analysts, will accelerate access to some Schedule I controlled substances to treat patients with serious mental illness.
President Donald Trump has signed an executive order (EO) to ease restrictions on the use of psychedelic drugs to treat serious mental illness, including post-traumatic stress disorder and brain trauma.
The EO directs the commissioner of the US Food and Drug Administration (FDA) to provide Commissioner’s National Priority Vouchers (CNPV)